| (B) | |||||
|---|---|---|---|---|---|
| Events/Patients | vs. TARE-ineligible | ||||
| TARE eligible | TARE-ineligible | HR (95% CI) | P | P interaction | |
| Age | 0.43 | ||||
| ≤65 | 19/77 | 11/21 | 2.34 (1.10–4.97) | 0.03 | |
| > 65 | 22/67 | 5/10 | 1.43 (0.54–3.80) | 0.47 | |
| Tumor size a | 0.28 | ||||
| ≤8.3 cm | 17/83 | 4/6 | 2.60 (1.02–6.67) | 0.046 | |
| >8.3 cm | 24/61 | 12/25 | 1.54 (0.87–2.73) | 0.14 | |
| MoRAL score b | 0.32 | ||||
| ≤200.6 | 9/39 | 1/5 | 0.76 (0.10–6.03) | 0.79 | |
| >200.6 | 32/105 | 15/26 | 2.02 (1.09–3.74) | 0.03 | |
| Child-Pugh class | 0.78 | ||||
| A | 39/142 | 14/29 | 1.74 (0.94–3.23) | 0.08 | |
| B | 2/2 | 2/2 | 2.33 (0.33–17.00) | 0.39 | |
| BCLC stage | 0.97 | ||||
| A | 14/71 | 9/20 | 2.22 (0.95–5.19) | 0.07 | |
| B | 27/73 | 7/11 | 2.27 (0.98–5.23) | 0.054 | |
a
Tumor size = 8.3 cm was the median value for the study population.
b
MoRAL score = 200.6 was the lower 75th percentile MoRAL score value for the study population.
BCLC, Barcelona Clinic Liver Cancer; HR, hazard ratio; MoRAL, model to predict tumor recurrence after living donor transplantation; TARE, transarterial radioembolization.